<?xml version='1.0' encoding='utf-8'?>
<document id="21726302"><sentence text="Combined clopidogrel and proton pump inhibitor therapy is associated with higher cardiovascular event rates after percutaneous coronary intervention: a report from the BASKET trial."><entity charOffset="9-20" id="DDI-PubMed.21726302.s1.e0" text="clopidogrel" /></sentence><sentence text="To investigate whether there is an increased risk of cardiac events with a combined therapy of clopidogrel and proton pump inhibitors (PPIs) after percutaneous coronary intervention (PCI)"><entity charOffset="95-106" id="DDI-PubMed.21726302.s2.e0" text="clopidogrel" /></sentence><sentence text="" /><sentence text="In the BAsel Stent Kosten Effektivitäts Trial (BASKET), all patients undergoing PCI received 6 months of clopidogrel and were analysed for the use of PPI therapy"><entity charOffset="105-116" id="DDI-PubMed.21726302.s4.e0" text="clopidogrel" /></sentence><sentence text=" Endpoints were major adverse cardiac events (MACE), myocardial infarction (MI), death and target vessel revascularization (TVR) after 36 months" /><sentence text="" /><sentence text="Of 801 patients with available discharge medication data, 109 (14%) received PPIs" /><sentence text=" Patients who received PPIs were older (66" /><sentence text="5 ± 10" /><sentence text="5 vs" /><sentence text=" 63" /><sentence text="3 ± 11" /><sentence text="3 years, P = 0" /><sentence text="006), more likely to be woman (80% vs" /><sentence text=" 69%, P = 0" /><sentence text="009) and have a history of diabetes (29" /><sentence text="6% vs" /><sentence text=" 17" /><sentence text="3%, P = 0" /><sentence text="002) or gastrointestinal ulcer disease (8" /><sentence text="3% vs" /><sentence text=" 3" /><sentence text="3%, P = 0" /><sentence text="015) and more often received nonsteroidal anti-inflammatory drugs (7" /><sentence text="3% vs" /><sentence text=" 2" /><sentence text="2%, P = 0" /><sentence text="003) and corticosteroids (11% vs"><entity charOffset="9-24" id="DDI-PubMed.21726302.s28.e0" text="corticosteroids" /></sentence><sentence text=" 3" /><sentence text="6%, P = 0" /><sentence text="001) but not aspirin (91"><entity charOffset="13-20" id="DDI-PubMed.21726302.s31.e0" text="aspirin" /></sentence><sentence text="7% vs" /><sentence text=" 97%, P = 0" /><sentence text="008) compared with those who did not receive PPIs" /><sentence text=" Patients who received PPI therapy had higher rates of MACE (30" /><sentence text="3% vs" /><sentence text=" 20" /><sentence text="8%, P = 0" /><sentence text="027) and MI (14" /><sentence text="7% vs" /><sentence text=" 7" /><sentence text="4%, P = 0" /><sentence text="01) but similar rates of death (9" /><sentence text="2% vs" /><sentence text=" 7" /><sentence text="4%, P = 0" /><sentence text="51) and TVR (20" /><sentence text="2% vs" /><sentence text=" 15" /><sentence text="3%, P = 0" /><sentence text="2) compared with those who did not" /><sentence text=" By multivariate analysis, diabetes (hazard ratio 1" /><sentence text="83, 95% confidence interval 1" /><sentence text="07-3" /><sentence text="15) and PPI use (hazard ratio 1" /><sentence text="88, 95% confidence interval 1" /><sentence text="05-3" /><sentence text="37) were the only independent risk factors for MI" /><sentence text="" /><sentence text="In a real-world PCI population, the combination of PPIs and clopidogrel was associated with a doubling of MI rates after 3 years"><entity charOffset="60-71" id="DDI-PubMed.21726302.s60.e0" text="clopidogrel" /></sentence><sentence text=" Even after correction for confounding factors, concomitant PPI use remained an independent predictor of outcome emphasizing the clinical importance of this drug-drug interaction" /><sentence text="" /></document>